Lactobacillus gasseri SBT2055 reduces postprandial and fasting serum non-esterified fatty acid levels in Japanese hypertriacylglycerolemic subjects

Lipids in Health and Disease

Volumn 13, Issue 1, 2014, Pages

  Ogawa, Akihiro ^a,b   Kadooka, Yukio ^b   Kato, Ken ^b   Shirouchi, Bungo ^a   Sato, Masao ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b SNOW BRAND MILK PRODUCTS CO LTD   (Japan)

Author keywords

Fermented milk products; Lactobacillus gasseri SBT2055; Non esterified fatty acid; Oral fat loading test; Postprandial lipid response; Probiotics; Triacylglycerol

Indexed keywords

FATTY ACID; HEMOGLOBIN A1C; PLACEBO; PROBIOTIC AGENT; TRIACYLGLYCEROL;

ADULT; ANTHROPOMETRIC PARAMETERS; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; FAT LOADING TEST MEAL; FATTY ACID BLOOD LEVEL; FEMALE; FERMENTED PRODUCT; FOOD INTAKE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTRIACYLGLYCEROLEMIA; LACTOBACILLUS GASSERI; MALE; METABOLIC DISORDER; MILK; POSTPRANDIAL STATE; SINGLE BLIND PROCEDURE; TEST MEAL; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

LACTOBACILLUS GASSERI; RATTUS;

CULTURED MILK PRODUCTS; FASTING; FATTY ACIDS, NONESTERIFIED; FEMALE; HUMANS; HYPERTRIGLYCERIDEMIA; JAPAN; LACTOBACILLUS; MALE; MIDDLE AGED; POSTPRANDIAL PERIOD; PROBIOTICS; SINGLE-BLIND METHOD; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 84895927176     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/1476-511X-13-36     Document Type: Article

References (38)

1. Distribution of the Lactobacillus acidophilus complex in human fecal specimens examined by restriction fragment length polymorphism of the 16S rRNA genes. Seto Y, Kimura A, Akai Y, Fujiwara S, Biosci Microflora 2003 22 75 83
2. Monitoring and survival of Lactobacillus gasseri SBT2055 in the human intestinal tract. Takahashi H, Fujita T, Suzuki Y, Benno Y, Microbiol Immunol 2006 50 867 870 10.1111/j.1348-0421.2006.tb03862.x 17116981
3. Establishment of orally-administered Lactobacillus gasseri SBT2055SR in the gastrointestinal tract of humans and its influence on intestinal microflora and metabolism. Fujiwara S, Seto Y, Kimura A, Hashiba H, J Appl Microbiol 2001 90 343 352 10.1046/j.1365-2672.2001.01251.x 11298228
4. Milk fermented by Lactobacillus gasseri SBT2055 influences adipocyte size via inhibition of dietary fat absorption in Zucker rats. Hamad EM, Sato M, Uzu K, Yoshida T, Higashi S, Kawakami H, Kadooka Y, Matsuyama H, Abd El-Gawad IA, Imaizumi K, Br J Nutr 2009 101 716 724 10.1017/S0007114508043808 18684338
5. Effects of milk fermented by Lactobacillus gasseri SBT2055 on adipocyte size in rats. Sato M, Uzu K, Yoshida T, Hamad EM, Kawakami H, Matsuyama H, Abd El-Gawad IA, Imaizumi K, Br J Nutr 2008 99 1013 1017 17977471
6. The probiotic Lactobacillus gasseri SBT2055 inhibits enlargement of visceral adipocytes and upregulation of serum soluble adhesion molecule (sICAM-1) in rats. Kadooka Y, Ogawa A, Ikuyama K, Sato M, Int Dairy J 2011 21 623 627 10.1016/j.idairyj.2011.02.001
7. Anti-obesity effect of Lactobacillus gasseri SBT2055 accompanied by inhibition of pro-inflammatory gene expression in the visceral adipose tissue in diet-induced obese mice. Miyoshi M, Ogawa A, Higurashi S, Kadooka Y, Eur J Nutr 2013 e-pub ahead of print 6 August 2013; doi:10.1007/s00394-013-0568-9
8. Regulation of abdominal adiposity by probiotics (Lactobacillus gasseri SBT2055) in adults with obese tendencies in a randomized controlled trial. Kadooka Y, Sato M, Imaizumi K, Ogawa A, Ikuyama K, Akai Y, Okano M, Kagoshima M, Tsuchida T, Eur J Clin Nutr 2010 64 636 643 10.1038/ejcn.2010.19 20216555
9. Effect of Lactobacillus gasseri SBT2055 in fermented milk on abdominal adiposity in adults in a randomized controlled trial. Kadooka Y, Sato M, Ogawa A, Miyoshi M, Uenishi H, Ogawa H, Ikuyama K, Kagoshima M, Tsuchida T, Br J Nutr 2013 110 1696 1703 10.1017/S0007114513001037 23614897
10. Inhibition of gastrointestinal lipolysis by orlistat during digestion of test meals in healthy volunteers. Carrière F, Renou C, Ransac S, Lopez V, De Caro J, Ferrato F, De Caro A, Fleury A, Sanwald-Ducray P, Lengsfeld H, Beglinger C, Hadvary P, Verger R, Laugier R, Am J Physiol Gastrointest Liver Physiol 2001 281 16 G28 11408251
11. U.S. Food and Drug Administration (fda): Orlistat (Marketed As Alli And Xenical) Information.: http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm180076.htm ] (accessed November 29, 2013
12. Acute effect of orlistat on postprandial lipaemia and free fatty acids in overweight patients with type 2 diabetes mellitus. Tan KC, Tso AW, Tam SC, Pang RW, Lam KS, Diabet Med 2002 19 944 948 10.1046/j.1464-5491.2002.00823.x 12421432
13. Mannooligosaccharides blended coffee beverage intake increases the fat level in feces. Kumao T, Fujii S, J Health Sci 2006 52 329 332 10.1248/jhs.52.329
14. Effect of coffee drink containing mannooligosaccharides on total amount of excreted fat in healthy adults. Kumao T, Fujii S, Asakawa A, Takehara I, Fukuhara I, J Health Sci 2006 52 482 485 10.1248/jhs.52.482
15. Effects of "coffee beverage" containing mannooligosaccharides from coffee on human abdominal fat by long term ingestion. Asano I, Fujii S, Ozaki K, Takahara I, Yano Y, Fukuhara I, Jpn J Food Eng 2005 6 133 141
16. Investigation of mannooligosaccharides blended coffee beverage on abdominal fat reduction in human. Asano I, Fujii S, Kaneko M, Takehara I, Fukuhara I, Jap J Med Pharm Sci 2006 55 93 103
17. Mode of action of orlistat. Guericiolini R, Int J Obes Relat Metab Disord 1997 21 12 S23 9225172
18. Effects of meals rich in either monounsaturated or saturated fat on lipid concentrations and on insulin secretion and action in subjects with high fasting triglyceride concentrations. Lopez S, Bermudez B, Ortega A, Varela LM, Pacheco YM, Villar J, Abia R, Muriana FJ, Am J Clin Nutr 2011 93 494 499 10.3945/ajcn.110.003251 21209225
19. Third report of the National Cholesterol Education Panel (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), Circulation 2002 106 3143 3421 12485966
20. Use of glycated haemoglobin (HbA1c) in the diagnosis of diabetes mellitus. Report of a World Health Organization Consultation, Diabetes Res Clin Pract 2011 93 299 309
21. Inhibitory effects of probiotics on pancreatic lipase [in Japanese]. Matsumura A, J Intest Microbiol 2010 24 287 292
22. Effects of heat-killed Lactobacillus pentosus S-PT84 on postprandial hypertriacylglycerolemia in rats. Zhou Y, Inoue N, Ozawa R, Maekawa T, Izumo T, Kitagawa Y, Kiso Y, Shibata H, Ikeda I, Biosci Biotechnol Biochem 2013 77 591 594 23470742
23. Postprandial metabolism of meal triglyceride in humans. Lambert JE, Parks EJ, Biochim Biophys Acta 1821 2012 721 726
24. Coordinated regulation of hormone-sensitive lipase and lipoprotein lipase in human adipose tissue in vivo: implications for the control of fat storage and fat mobilization. Frayn KN, Coppack SW, Fielding BA, Humphreys SM, Adv Enzyme Regul 1995 35 163 178 7572342
25. The effects of rosiglitazone on fatty acid and triglyceride metabolism in type 2 diabetes. Tan GD, Fielding BA, Currie JM, Humphreys SM, Désage M, Frayn KN, Laville M, Vidal H, Karpe F, Diabetologia 2005 48 83 95 10.1007/s00125-004-1619-9 15619071
26. Rosiglitazone: a review of its use in the management of type 2 diabetes mellitus. Wagstaff AJ, Goa KL, Drugs 2002 62 1805 1837 10.2165/00003495- 200262120-00007 12149047
27. The increase in abdominal subcutaneous fat depot is an independent factor to determine the glycemic control after rosiglitazone treatment. Kim SK, Hur KY, Kim HJ, Shim WS, Ahn CW, Park SW, Cho YW, Lim SK, Lee HC, Cha BS, Eur J Endocrinol 2007 157 167 174 10.1530/EJE-07-0043 17656594
28. The latest on the effect of prior exercise on postprandial lipaemia. Maraki MI, Sidossis LS, Sports Med 2013 43 463 481 10.1007/s40279-013-0046-9 23580393
29. Black-white differences in postprandial triglyceride response and postheparin lipoprotein lipase and hepatic triglyceride lipase among young men. Friday KE, Srinivasan SR, Elkasabany A, Dong C, Wattigney WA, Dalferes E Jr, Berenson GS, Metabolism 1999 48 749 754 10.1016/S0026-0495(99)90175-0 10381150
30. Suppressive effect of oolong tea polymerized polyphenols-enriched oolong tea on postprandial serum triglyceride elevation [in Japanese]. Hara Y, Moriguchi S, Kusumoto A, Nakai M, Ono Y, Abe K, Ohta H, Shibata H, Kiso Y, Egawa K, Jpn Pharmacol Ther 2004 32 335 342
31. Effect of tea catechins on postprandial plasma lipid responses in human subjects. Unno T, Tago M, Suzuki Y, Nozawa A, Sagesaka YM, Kakuda T, Egawa K, Kondo K, Br J Nutr 2005 93 543 547 10.1079/BJN20041379 15946418
32. Oligomeric procyanidins in apple polyphenol are main active components for inhibition of pancreatic lipase and triglyceride absorption. Sugiyama H, Akazome Y, Shoji T, Yamaguchi A, Yasue M, Kanda T, Ohtake Y, J Agric Food Chem 2007 55 4604 4609 10.1021/jf070569k 17458979
33. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. Hokanson JE, Austin MA, J Cardiovasc Risk 1996 3 213 219 10.1097/00043798-199604000-00014 8836866
34. A high concentration of fasting plasma non-esterified fatty acids is a risk factor for the development of NIDDM. Paolisso G, Tataranni PA, Foley JE, Bogardus C, Howard BV, Ravussin E, Diabetologia 1995 38 1213 1217 10.1007/BF00422371 8690174
35. FFA cause hepatic insulin resistance by inhibiting insulin suppression of glycogenolysis. Boden G, Cheung P, Stein TP, Kresge K, Mozzoli M, Am J Physiol Endocrinol Metab 2002 283 12 E19 12067837
36. The role of non-esterified fatty acids in the deterioration of glucose tolerance in Caucasian subjects: results of the Paris Prospective Study. Charles MA, Eschwège E, Thibult N, Claude JR, Warnet JM, Rosselin GE, Girard J, Balkau B, Diabetologia 1997 40 1101 1106 10.1007/s001250050793 9300248
37. Are increased plasma non-esterified fatty acid concentrations a risk marker for coronary heart disease and other chronic diseases? Frayn KN, Williams CM, Arner P, Clin Sci 1996 90 243 253 8777830
38. Effect of functional yogurt NY-YP901 in improving the trait of metabolic syndrome. Chang BJ, Park SU, Jang YS, Ko SH, Joo NM, Kim SI, Kim CH, Chang DK, Eur J Clin Nutr 2011 65 1250 1255 10.1038/ejcn.2011.115 21697819